United Therapeutics’ UTHR fourth-quarter 2024 ... for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications. Tyvaso DPI recorded sales of $273.2 million ...

Good morning and welcome to the United Therapeutics Corporation ... and at the International Society for Heart and Lung Transplantation conference in Boston on April 27, to the 30.

NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

United Therapeutics’ key phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag in PAH indications ...

United Therapeutics Corporation (NASDAQ ... And at the International Society for Heart and Lung Transplantation Conference in Boston on April twenty-seventh to the thirtieth.

United Therapeutics Corporation beats earnings expectations ... And at the International Society for Heart and Lung Transplantation Conference in Boston on April twenty-seventh to the thirtieth.

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq ... hypertension associated with interstitial lung disease (PH-ILD) and, to a lesser extent, increased ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...